Team Trivia! Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

Clinical Care Options in collaboration with the National Eczema Association is hosting an innovative and engaging symposium IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills Curriculum to Support Evidence-Based Treatment Decisions combining education with friendly competition is set to revolutionize learning about IL-13 inhibitors in moderate to severe atopic dermatitis. Scheduled for March 9, 2025, in Orlando, Florida, in conjunction with the American Academy of Dermatology annual meeting.  This unique event promises to challenge and enlighten healthcare professionals through an interactive team trivia format.

Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense itching and recurrent eczematous lesions, significantly impacting patients’ quality of life. Recent advancements in understanding AD pathogenesis have highlighted the crucial role of interleukin-13 (IL-13) in skin barrier dysfunction and inflammation, leading to the development of targeted IL-13 inhibitor therapies.

Event Highlights

• Date and Time: March 9, 2025, 7:00 PM – 9:00 PM ET (in-person), 7:30 PM – 9:00 PM ET (virtual)
• Location: Hilton Orlando, Orange Ballroom E&F 6001 Destination Parkway, Orlando, Florida 32819
• Format: In-person and virtual participation options
• Register Here

Faculty include:

Andrew F. Alexis, MD, MPH

Professor of Clinical Dermatology
Weill Cornell Medicine
New York, New York

Daniel C. Butler, MD
Assistant Dean of Student Affairs
Associate Professor
University of Arizona College of Medicine
Tucson, Arizona

Shawn G. Kwatra, MD

Dr. Joseph W. Burnett Professor and Chair
Department of Dermatology
University of Maryland School of Medicine
Baltimore, Maryland

This symposium offers a unique blend of education and entertainment:

• Team-based trivia competition with leaderboard rankings
• Expert-led discussions on atopic dermatitis management
• Real-time case analyses
• Interactive voting on case management scenarios using iPads
• Complimentary dinner and drinks for in-person attendees

Learning Objectives
Participants will have the opportunity to:

1. 1. Deepen their understanding of IL-13’s role in moderate to severe atopic dermatitis
   2. Evaluate the latest evidence and guidelines for IL-13 targeting therapies
   3. Enhance their ability to identify suitable candidates for advanced biologic therapies
      targeting IL-13

Who Should Attend?

This event is tailored for:

• • • Dermatologists
    • Allergist/Immunologists
    • Specialized nurse practitioners
    • Physician associates

Accessibility

The organizers have prioritized accessibility:

• Free registration for all participants
• Support available for attendees with special needs
• Virtual attendance option for remote participation

While not offering CME/CE credits, this educational activity is made possible through an educational grant from Lilly. It is provided by Clinical Care Options, LLC in collaboration with Practicing Clinicians Exchange, LLC and the National Eczema Association.

This innovative symposium represents an exciting opportunity for healthcare professionals to test their knowledge, learn from experts, and enhance their skills in managing moderate to severe atopic dermatitis. By combining the latest insights on IL-13 inhibitors with an engaging trivia format, attendees are sure to come away with valuable knowledge that can directly impact patient care.

Register Here